Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.

Anthony V. DAmico,Wanling Xie,Elizabeth McMahon,Marian Loffredo,Shana Medeiros,David Joseph,James W. Denham,Parvesh Kumar,Glenn J. Bubley,Molly Sullivan,Richard Hellwig,Juan Carlos Vera,Rolf Freter,W. Jeffrey Baker,Jeffrey Y.C. Wong,Andrew A. Renshaw,Philip W. Kantoff

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.

2021

Anthony V. DAmico
Wanling Xie
Elizabeth McMahon
Marian Loffredo
Shana Medeiros
David Joseph
James W. Denham
Parvesh Kumar
Glenn J. Bubley
Molly Sullivan
Richard Hellwig
Juan Carlos Vera
Rolf Freter
W. Jeffrey Baker
Jeffrey Y.C. Wong
Andrew A. Renshaw
Philip W. Kantoff

PURPOSEAlthough docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits ...

Keywords:

Internal medicine
Medicine
Docetaxel
Androgen deprivation therapy
Oncology
Randomized controlled trial
Prostate cancer
MEDLINE

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations